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Expansion of a polyglutamine-encoding trinucleotide CAG repeat in the androgen receptor (AR) to more
than 37 repeats is responsible for the X-linked neuromuscular disease spinal and bulbar muscular
atrophy (SBMA). Here we evaluated the effect of polyglutamine length on AR function in Xenopus oo-
cytes. This allowed us to correlate the nuclear AR concentration to its capacity for speciﬁc DNA binding
and transcription activation in vivo. AR variants with polyglutamine tracts containing either 25 or 64
residues were expressed in Xenopus oocytes by cytoplasmic injection of the corresponding mRNAs. The
intranuclear AR concentration was monitored in isolated nuclei and related to speciﬁc DNA binding as
well as transcriptional induction from the hormone response element in the mouse mammary tumor
virus (MMTV) promoter. The expanded AR with 64 glutamines had increased capacity for speciﬁc DNA
binding and a reduced capacity for transcriptional induction as related to its DNA binding activity. The
possible mechanism behind these polyglutamine-induced alterations in AR function is discussed.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Androgenic hormones play a vital role in many biological pro-
cesses in various parts of the body including reproductive organs,
kidney, liver, bone, muscle and brain. They exert their role via
binding to the androgen receptor (AR), a ligand-activated steroid
hormone receptor that acts as a transcription factor to control the
expression of androgen-dependent genes [1]. The N-terminal
transactivation domain (NTD) of the AR protein contains a poly-
morphic polyglutamine (polyQ) tract which has been linked to
spinal and bulbar muscular atrophy (SBMA, Kennedy's disease) [2],
a disorder characterized by progressive neuromuscular weakness
which develops when its length exceeds 37 residues [3]. The ex-
panded polyQ tract in AR has been demonstrated to alter tran-
scriptional activity of AR in different ways in different cell types.
Several studies have shown that AR transcriptional activity in-
versely correlates with the length of this tract [4–7], however not
all reports are in agreement. Thus, it was shown that AR tran-
scriptional activity is positively affected by increasing polyQ repeatr B.V. This is an open access article
gen response element(s); bp,
mmary tumor virus; NTD, N-
l and bulbar muscular atro-
ox 285, SE-17177 Stockholm,length in skeletal muscle cells [8] thus arguing that the effect of an
extended polyQ repeat on AR function is context dependent, for
example due to interactions with tissue-speciﬁc co-activators. In-
terestingly, the polyQ repeat length also affects AR stability, pos-
sibly because of altered protein folding [7,9] and recent studies
demonstrate beneﬁcial effects on the AR polyQ disease in a mouse
model by disrupting the SUMOylation of AR [10].
Although the cause of SBMA is expansion of the CAG repeats in
the AR gene the exact disease mechanism remain unclear. We
decided to use Xenopus oocytes to look more closely at the func-
tion of the AR with an expanded polyQ tract. The large size of
these cells allows quantiﬁcation of intranuclear receptor con-
centration, sequence speciﬁc DNA binding and AR target gene
activation [11]. As a gene target we used the enhancer and pro-
moter of the mouse mammary tumor virus (MMTV) since this is a
useful model system for studies of hormone regulation by gluco-
corticoids [12] progestins and androgens [11].
An advantage of the Xenopus oocyte system is that proteins
may be expressed in variable amounts by injection of corre-
sponding in vitro transcribed mRNAs [12]. The DNA reporter is
introduced by intranuclear injection of circular single-stranded
(ss) DNA, which in our case yielded approximately 600 million
gene copies of the MMTV long terminal repeat and all copies are
active in terms of speciﬁc protein-DNA binding and chromatin
remodeling [12]. Importantly, intranuclear injection of ssDNA in
Xenopus oocytes leads to second-strand DNA synthesis coupled to
assembly of a tightly organized chromatin structure [12]. Becauseunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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factor-DNA interactions can be quantiﬁed with high precision by
dimethylsulfate (DMS) in vivo footprinting [11,13]. It is straight-
forward to isolate the cell nucleus of the oocyte by manual dis-
section and hence to analyze its protein content.
Here we show that AR with a pathological polyQ tract of 64
residues (ARQ64) has increased capacity for speciﬁc DNA binding.
Interestingly, this increase did not correlate with an increase in
transcription induction at the MMTV promoter. Hence the tran-
scriptional activity of ARQ64 was signiﬁcantly reduced in com-
parison to the wild type ARQ25 as related to its DNA binding ac-
tivity. The possible mechanism for this effect is discussed.2. Materials and methods
2.1. Reagents, plasmids and constructs
AR ligands used were R1881 (PerkinElmer Inc., Waltham, MA),
as 1103 M in EtOH and MDV3100 (enzalutamide) as
1102 M in DMSO (from Selleck Chemicals Co. Ltd., Houston,
TX). The reporter pMMTV:M13 contains the 1.2 kb MMTV LTR
fused to the HSV TK gene and its transfer to M13 was described
[12], as has the production of mRNAs. The cDNA coding for the
different AR variants were based on pβhAR described before [11],
that contains the full length human AR, a kind gift from Dr. Jeming
Wong [14]. AR variants with polyQ tracts of different length were
generated by restriction cloning. A fragment within AR containing
the CAG repeat ﬂanked by XmaI and EcoRI restriction sites was
excised from pβhAR and replaced with fragments containing 0, 13,
25, or 64 CAG repeats. The AR-Q64 cDNA was shown to be con-
taminated with AR variants containing shorter repeat(s) than Q64.
The contaminants were removed by re-transformation of the
pβAR-Q64 plasmid in E-coli cells with reduced recombination
activity (SURE cells™, Stratagene).
2.2. Oocyte injections
The animal experiments were conducted according to a deﬁnedA B
C D
Fig. 1. Experimental design and quantiﬁcation of AR in oocyte nuclei. (A) Xenopus oocyte
harvested for analysis at indicated time (h). (B) Increasing concentrations of [3H]-R1881
ARQ25 and next day taken for analysis of [3H]-R1881 in manually isolated nuclei. (C) Ooc
and were then analyzed either by quantiﬁcation of nuclear [3H]-R1881 or (D) by Westeprotocol approved by a local ethical committee (Stockholm N.
ethical committee for animal experiments, permit no. N21/12 and
N6/15). DNA and mRNA injections into Xenopus laevis oocytes have
been described previously [15] the protocol is outlined in Fig. 1A. A
synthetic androgenic hormone agonist, R1881, was added at
100 nM ﬁnal concentration, was added immediately after mRNA
injection. An aliquot of eight mRNA injected oocytes was in-
cubated in [3H]-R1881 for quantiﬁcation of intranuclear AR (see
below). Oocytes were incubated at 21 °C after mRNA injections
and until they were harvested ∼28 h later [11].
2.3. Quantiﬁcation of intranuclear AR by speciﬁc [3H]-R1881 binding
Eight oocytes from each pool of mRNA injected oocytes were
placed in a separate 96-well plate containing OR2 buffer [15] and
100 nM concentration of [3H]-R1881 (PerkinElmer, 81.2 Ci/mmol).
Since Xenopus oocytes contain endogenous androgens [16] the
concentration of radioactive hormone was titrated to obtain near
complete exchange of any endogenous ligand with the radio-
actively labeled probe this titration showed that [3H]-R1881 con-
centration above 50 nM was enough to fully saturate the ex-
pressed AR with radioactive ligand (see results, Fig. 1B). 28 h after
mRNA injections, the intranuclear AR protein was analyzed as the
radioactivity detectable in isolated oocyte nuclei. A [3H]-toluene
standard (PerkinElmer) was used to estimate the efﬁciency for
tritium (see results, Fig. 1C). The AR concentration was calculated
assuming that one oocyte nucleus has a volume of 40 nl [17].
Routinely, three nuclei were dissected in duplicate for each data
point. Nuclear [AR] was deﬁned as the average of the two samples
after subtraction of nonspeciﬁc radioactivity (see results).
2.4. Quantiﬁcation of the MMTV transcription by S1-nuclease pro-
tection and speciﬁc DNA binding by DMS in vivo footprinting
Quantiﬁcation of the MMTV transcription by S1-nuclease pro-
tection and speciﬁc DNA binding by DMS in vivo footprinting was
done as described previously [18]. Nonlinear model ﬁt of data
points were generated using the software CurveExpert Pro V.2.2.0.
The amount of intranuclear plasmid DNA was recovered ass were injected with mRNA into the cytoplasm and with ssDNA into the nucleus and
were incubated with oocytes either injected or not injected with mRNA coding for
ytes were injected with the indicated amounts of mRNA coding for ARQ25 or ARQ64
rn blot (WB), A.U. indicates arbitrary units.
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extension in parallel with a DNA standard [13].3. Results and discussion
3.1. ARQ25 and the ARQ64 expression and quantiﬁcation in Xenopus
oocytes
We previously used Western blot (WB) to monitor the amount
of AR in Xenopus oocytes [11]; an alternative strategy to quantify
steroid receptors is to monitor the hormone-receptor complex
using a tritiated hormone-ligand as a probe [19]. The latter strat-
egy provides information about the absolute amount of hormone-
receptor complex since there is one hormone-binding site in each
receptor molecule. Xenopus oocytes contain endogenous andro-
gens so it was important to test whether a tritiated hormone li-
gand could compete efﬁciently for binding to the receptor in
presence of the unlabeled endogenous hormone. Oocytes pre-
viously injected with ARQ25 mRNA and incubated with increasing
concentration of the tritium labeled androgen agonist R1881 [20]
were taken for nuclear dissection. Oocytes not injected with AR
mRNA served as negative controls, indicated as blank oocytes in
Fig. 1B. Radioactivity analysis of nuclear extracts showed that a
[3H]-R1881concentration above ∼50 nM efﬁciently competed for
any endogenous ligand since the AR dependent nuclear radio-
activity reached a plateau at this level and no further increase
occurred even at 400 nM [3H]-R1881 (Fig. 1B). The nonspeciﬁc
radioactivity recovered in blank oocyte nuclei showed a linear
relationship with increasing [3H]-R1881concentration in the
medium. The addition of non-radioactive R1881 together with the
tritiated ligand competed efﬁciently as expected and reduced the
nuclear radioactivity accordingly (data not shown).
Xenopus oocytes are ﬁlled with yolk protein and lipophilic
substances. Steroids such as [3H]-R1881 are also rather lipophilic.
We addressed this potential source of error in quantiﬁcation of AR
based on radioactive ligand by measuring the amount of [3H]-
R1881 ligand in extracts from whole oocytes and from manually
isolated nuclei that were either not injected or injected with
ARQ25 mRNA (Supplement 1A). This showed a 0.52 mM con-
centration of nuclear AR in the oocytes injected with AR mRNA
and a signal to noise ratio of 5.1 corresponding to 0.02 pmol of
speciﬁcally bound hormone ligand per nucleus based on a nuclear
volume of 40 nl [17]. The total amount of hormone in the intact
oocyte was 1.2–1.5 pmol/cell and thus a 45-fold higher amount
than in AR containing nuclei or 260-fold higher than nuclei in
oocyte not injected with AR mRNA (Supplement 1A). The level of
radioactivity in the cytosol was about the same whether AR was
expressed or not and higher than in the media. This illustrates the
differential distribution of the lipophilic steroid R1881 in water
solution compared to the lipid-containing oocyte cytosol. This was
in sharp contrast to the nucleus, where the background level of
radioactive ligand was low enough to allow a reproducible quan-
tiﬁcation of the AR-dependent amounts.
mRNAs coding for the polyQ variants ARQ25 and ARQ64 were
injected into the cytoplasm of two different pools of Xenopus oo-
cytes and resulting protein expression was analyzed in manually
isolated oocyte nuclei either by monitoring [3H]-R1881 radio-
activity (Fig. 1C) or by WB analysis of nuclear extracts (Fig. 1D).
Both methods show that the stepwise increase of injected of
ARQ25 mRNA rendered a linear increase of expressed ARQ25
protein (Fig. 1C and D). However, the ARQ64 expression generated
by mRNA amounts above 6 ng per oocyte reached a plateau in-
dicating that saturation in protein expression was achieved (see
Fig. 1C and D). This comparison between the quantiﬁcation of
nuclear AR based on retained [3H]-R1881 and WB showed the twomethods to correlate well. However, we found that WB tends to
produce more variable results and furthermore the WB method
did not provide information about absolute amounts of receptor.
Both methods have been used in this work, but we favor the [3H]-
R1881-based approach for intranuclear AR quantiﬁcation.
One problem that we encountered was that the ARQ64 ex-
pressed protein migrates on SDS PAGE as a double band. The faster
moving band constituted 10–25% of the total signal (cf. Fig. 1D,
lanes 5–8) and was not present in other AR variants with smaller
polyQ length which always appeared as a single band (cf Fig. 1D,
lanes 2–4). The faster migrating band of ARQ64 showed an elec-
trophoretic mobility similar to ARQ25 (Fig. 1D). Restriction enzyme
analysis of the cDNA of ARQ64 as well as WB using different AR
antibodies, and in addition one antibody directed to long polyQ
repeats [21], indicated that the ARQ64 plasmid used for in vitro
mRNA transcription was contaminated by an AR variants con-
taining shorter polyQ repeats of a similar size as ARQ25 (data not
shown and Supplement 1B). Since DNA-repetitive sequences are
prone to be deleted by recombination during ampliﬁcation in
E-coli, we re-ampliﬁed the ARQ64 cDNA from a single colony using
E-coli with reduced recombination capacity (Sure Cells™, Strata-
gene). RNA produced from this plasmid that was injected into
oocytes gave rise to a single band of ARQ64 by WB (Supplement
1B, compare lanes 2 and 4). This puriﬁed ARQ64 template was
used in most of the experiments comparing ARQ64 to ARQ25 (c.f.
Fig. 2).
3.2. Functional comparison of ARQ25 and ARQ64
Groups of oocytes were injected with increasing amounts of
mRNA coding for ARQ25 or ARQ64 as indicated (Fig. 1A) followed
by 3 ng of ssDNA of pMMTV:M13 harboring the MMTV enhancer
and promoter. Aliquots of oocytes from each group were collected
after mRNA injection and incubated with ∼100 nM [3H]-R1881 and
after 28 h the oocytes were harvested and analyzed for nuclear AR
concentration, AR-driven MMTV transcription (Fig. 2A), and se-
quence speciﬁc AR-DNA binding (Fig. 2B) by DMS in vivo
footprinting.
A comparison of the two AR variants did not show any differ-
ence in the capacity to induce MMTV transcription when related
to the nuclear AR concentration (see Fig. 2A, lower diagram).
However, the sequence-speciﬁc DNA binding, deﬁned as DMS
methylation protection (Fig. 2B, see protected bands marked with
open circles) plotted as a function of nuclear AR concentration
(Fig. 2C) demonstrated a stronger DNA binding by ARQ64. Im-
portantly, a diagram showing AR-driven transcription as a function
of AR-DNA binding activity revealed a 2.5-fold increased tran-
scriptional response for ARQ25 as compared to ARQ64 (Fig. 2D).
This result was reproduced twice (c.f. Supplement 2). In all three
experiments a more robust transcriptional response was seen by
ARQ25 as compared to ARQ64 in relation to its speciﬁc DNA
binding activity. These results argue for a functional dissociation
between the DNA binding event and the transcriptional induction
seen with the ARQ64 variant.
3.3. No difference between ARQ25 and ARQ64 in androgen agonist-
or antagonist-dependent nuclear translocation
The AR is transported into the cell nucleus in a hormone-de-
pendent fashion. The kinetics of the hormone-dependent nuclear
translocation could not be addressed since Xenopus oocytes con-
tain endogenous androgens. Instead we analyzed the hormone-
dependent nuclear localization with the ARQ25 and ARQ64 var-
iants at equilibrium, i.e. 6 h after addition of the agonist, R1881, or
an antagonist, enzalutamide; the latter is an antiandrogen that has
been shown to reduce nuclear translocation of AR in Xenopus
Fig. 2. Comparison of ARQ25 and ARQ64. (A) Quantiﬁcation of MMTV transcription by S1 nuclease protection analysis of oocytes injected with either 2.1; 3.1; 4.6 or 6.9 ng
ARQ25 mRNA 2.7; 4.1; 6.1 or 9.2 ng of ARQ64 mRNA and then 3 ng ssDNA pMMTV:M13 and exposed to 100 nM R1881. A.U. indicates arbitrary units. The diagram below
shows MMTV transcription as a function of nuclear [AR](mM) based on [3H]-R1881 analysis. Gray shadow indicates the curve ﬁtting of all data by software Curve Expert Pro
v.2.2.0. (B) Autoradiogram of primer extension from DMS in vivo footprinting of aliquots of the same oocytes as in Fig. 2A. Speciﬁc DNA sites for AR (ARE) are indicated on the
left side together with binding sites for other proteins (not expressed here), radioactive bands protected in presence of AR, i.e. DMS methylation protected, are marked to the
right with empty circles and reference bands for loading control as ﬁlled circles. Quantiﬁcation of the average value of the protected bands, two lanes per oocyte pool, is
shown as columns below with the average deviation of double samples as error bars. The last lane was lost in ARQ25. (C) AR-DNA binding, based on DMS methylation
protection, plotted as a function of intranuclear [AR], based on quantiﬁcation of nuclear [3H]-R1881. The curves are calculated based on the Curve Expert Pro v 2.2.0 software.
(D) Transcription of MMTV RNA analyzed by S1 nuclease was plotted as a function of AR-DNA binding activity from DMS in vivo footprinting.
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or ARQ64 were incubated either with 5 nM R1881 or 1 mM en-
zalutamide and the nuclear and cytosolic extracts were analyzed
by WB. This showed a strong tendency for the AR to be localized in
the nucleus in the presence of the agonist R1881, where 90% of
total AR was nuclear for both AR variants (Fig. 3A), as well as a
distinct reduction of the nuclear uptake in the presence of en-
zalutamide, where about 58% was nuclear (Fig. 3B) for both AR
variants. Hence the androgen antagonist caused about a four-foldincrease in the percentage of cytosolic AR for both AR variants.
We conclude that there is no difference in the nuclear and
cytoplasmic distribution of the ARQ25 and the ARQ64. The ex-
periment also indicates that the ligand binding speciﬁcity for the
ligands tested here is the same for both AR variants.
3.4. AR with shorter polyQ repeats, ARQ0 and ARQ13, showed no
difference in transcriptional activity compared to ARQ25
Our ﬁnding of a reduced capacity by ARQ64 to drive MMTV
AB
Fig. 3. Comparison of nuclear and cytosolic distribution of ARQ25 and ARQ64 (A) in
presence of androgen agonist R1881 or (B) androgen antagonist enzalutamide.
Oocytes were injected with 3.5 ng ARQ25 mRNA or 6.9 ng of ARQ64 mRNA fol-
lowed by 3 ng ssDNA pMMTV:M13 as in Fig. 1A. 28 h later oocytes were harvested
and processed for SDS PAGE and WB (see Section 2). 0.75 of oocyte equivalent of
cytosol or nuclear extract was applied on each lane. The smaller ARQ64 sub-band of
MW ∼120 kDa was also present in this experiment since the re-ampliﬁcation of the
pβARQ64 described above was done later. The ratio of the main band and the
smaller band of ARQ64 remained constant when comparing cytosolic and nuclear
ARQ64 (data not shown).
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Fig. 2D) encouraged us also to address the biological activity of AR
with shorter polyQ repeats; hence we developed ARQ0 and ARQ13
constructs. The in vitro transcribed mRNA was injected into oo-
cytes and 28 h later nuclei and cytosol was separated by manual
dissection and the relative amounts of AR in nuclear and cytosol
extracts estimated by WB. This indicated an average nuclear AR
localization of 98, 97 and 96% for ARQ0; Q13 and Q25, respectively.
Thus there was no difference in nuclear uptake between AR25Q
and AR variants with shorter polyglutamine tracts (data not
shown).
Oocytes injected with the three AR variants Q0, Q13 and Q25
followed by the ssDNA injection, 3 ng MMTV: M13, three in-
dependent experiments did not generate any consistent difference
in expression (Supplement 3B), DNA binding or transcription
(Supplement 3A and C) when relating these activities to the re-
lative intranuclear AR levels, here monitored by WB. We conclude
that there was no major difference in AR function for the AR var-
iants containing non-pathological polyQ repeats, suggesting that
the effects observed for ARQ64 are speciﬁc for the polyQ-ex-
panded AR. However, this ﬁnding does not exclude functional
differences of AR with shorter repeats in another promoter- or
cellular context. As mentioned above, both increased [8] and de-
creased [5] transcriptional activity have been reported withincreasing length of the polyQ repeat.
3.5. Final remarks
We observed a difference in sequence-speciﬁc DNA binding by
ARQ64. Unexpectedly, this AR variant showed increased capacity
to bind speciﬁc DNA sequence in a chromatinized template in vivo.
This difference was distinct when comparing DNA binding as a
function of nuclear AR concentration (Fig. 2C and Supplement 2C),
but it was even more robust when relating the DNA binding to its
capacity to induce transcription (Fig. 2D and Supplement 2D). In
the latter case the ARQ25 had a much stronger capacity to induce
transcription than the ARQ64 variant. Importantly, this difference
was not apparent when relating MMTV transcription to the nu-
clear AR concentration (Fig. 2A, lower diagram and Supplement 2,
lower diagram). This is unexpected since all steroid receptors
show hormone-dependent speciﬁc DNA binding activity as an
important step in the chain of events involved in the hormone-
driven gene induction. It suggests that ARQ64 has a reduced ca-
pacity to convert the DNA binding event into a transcriptional
response.
Interestingly, inhibiting SUMOylation of AR with an expanded
polyQ repeat counteracted the signiﬁcant loss of transactivation
caused by polyQ expansion and ameliorated the mutant AR-
mediated disease in a mouse model [10]. A deubiquitinating en-
zyme Usp12 was recently shown to act as a coactivator for AR in
prostate cancer cells [22]. If such modiﬁcations occur in oocytes
and play a role in the process involved in converting a DNA
binding event into a transcriptional response then the elongated
polyQ of the ARQ64 variant might reduce or alter this process. We
speculate that posttranslational modiﬁcations are changed in the
context of an extended polyQ and that this contributes to the re-
duced transcriptional response with ARQ64.
We are the ﬁrst to report increased speciﬁc DNA binding ca-
pacity of the ARQ64 in vivo. This important step in the mechanism
of action of androgens is conﬁned to the chromatin target and the
transactivating factor, i.e. AR. It remains to be determined whether
this result also applies to other AR driven enhancers and in other
cellular context.Conﬂict of interest
The authors have declared no conﬂicts of interest [23].Acknowledgments
This work was supported by the Swedish Cancer Society (#14
0792) to SB and ÖW; by intramural research funds from the Na-
tional Institute for Neurological Disorders and Stroke (NINDS)
(Grant no. NS003037), National Institutes of Health to LCB and
KHF. ÖW is associate member of the European Commission Net-
work of Excellence, EpiGeneSys. LCB was part of the National In-
stitute of Health (KHF) and Karolinska Institute (Dr. Nico Dantuma)
Graduate Partnership in Neuroscience. We also thank Dr. Nico
Dantuma for helpful comments on this manuscript. We are
grateful to Jorma J. Palvimo for providing unlabeled R1881 and
enzalutamide.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.bbrep.2015.07.014.
S. Belikov et al. / Biochemistry and Biophysics Reports 3 (2015) 134–139 139References
[1] O.A. Janne, J.J. Palvimo, P. Kallio, M. Mehto, Androgen receptor and mechanism
of androgen action, Ann. Med. 25 (1993) 83–89.
[2] W.R. Kennedy, M. Alter, J.H. Sung, Progressive proximal spinal and bulbar
muscular atrophy of late onset. A sex-linked recessive trait, Neurology 18
(1968) 671–680.
[3] A.R. La Spada, E.M. Wilson, D.B. Lubahn, A.E. Harding, K.H. Fischbeck, Andro-
gen receptor gene mutations in X-linked spinal and bulbar muscular atrophy,
Nature 352 (1991) 77–79.
[4] N.L. Chamberlain, E.D. Driver, R.L. Miesfeld, The length and location of CAG
trinucleotide repeats in the androgen receptor N-terminal domain affect
transactivation function, Nucleic Acids Res. 22 (1994) 3181–3186.
[5] P. Kazemi-Esfarjani, M.A. Triﬁro, L. Pinsky, Evidence for a repressive function of
the long polyglutamine tract in the human androgen receptor: possible pa-
thogenetic relevance for the (CAG)n-expanded neuronopathies, Hum. Mol.
Genet. 4 (1995) 523–527.
[6] H. Nakajima, F. Kimura, T. Nakagawa, D. Furutama, K. Shinoda, A. Shimizu,
N. Ohsawa, Transcriptional activation by the androgen receptor in X-linked
spinal and bulbar muscular atrophy, J. Neurol. Sci. 142 (1996) 12–16.
[7] A.P. Lieberman, G. Harmison, A.D. Strand, J.M. Olson, K.H. Fischbeck, Altered
transcriptional regulation in cells expressing the expanded polyglutamine
androgen receptor, Hum. Mol. Genet. 11 (2002) 1967–1976.
[8] R.L. Sheppard, E.E. Spangenburg, E.R. Chin, S.M. Roth, Androgen receptor
polyglutamine repeat length affects receptor activity and C2C12 cell devel-
opment, Physiol. Genomics 43 (2011) 1135–1143.
[9] P. Davies, K. Watt, S.M. Kelly, C. Clark, N.C. Price, I.J. McEwan, Consequences of
poly-glutamine repeat length for the conformation and folding of the andro-
gen receptor amino-terminal domain, J. Mol. Endocrinol. 41 (2008) 301–314.
[10] S.L. Reddy, J.P. Chua, Z. Yu, E. Giorgetti, H.L. Montie, S. Mukherjee, J. Higgins,
R.C. McEachin, D.M. Robins, D.E. Merry, J.A. Iñiguez-Lluhí, A.P. Lieberman,
Disrupting SUMOylation enhances transcriptional function and ameliorates
polyglutamine androgen receptor-mediated disease, J. Clin. Investig. 125
(2015) 831–845.
[11] S. Belikov, C. Oberg, T. Jaaskelainen, V. Rahkama, J.J. Palvimo, O. Wrange, FoxA1
corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates
the effect of MDV3100 (Enzalutamide), Mol. Cell. Endocrinol. 365 (2013)95–107.
[12] S. Belikov, B. Gelius, G. Almouzni, O. Wrange, Hormone activation induces
nucleosome positioning in vivo, EMBO J. 19 (2000) 1023–1033.
[13] S. Belikov, B. Gelius, O. Wrange, Hormone-induced nucleosome positioning in
the MMTV promoter is reversible, EMBO J. 20 (2001) 2802–2811.
[14] J. Li, J. Fu, C. Toumazou, H.G. Yoon, J. Wong, A role of the amino-terminal
(N) and carboxyl-terminal (C) interaction in binding of androgen receptor to
chromatin, Mol. Endocrinol. 20 (2006) 776–785.
[15] C. Astrand, S. Belikov, O. Wrange, Histone acetylation characterizes chromatin
presetting by NF1 and Oct1 and enhances glucocorticoid receptor binding to
the MMTV promoter, Exp. Cell Res. 315 (2009) 2604–2615.
[16] W.H. Yang, L.B. Lutz, S.R. Hammes, Xenopus laevis ovarian CYP17 is a highly
potent enzyme expressed exclusively in oocytes. Evidence that oocytes play a
critical role in Xenopus ovarian androgen production, J. Biol. Chem. 278 (2003)
9552–9559.
[17] P. Hausen, R. Metta, The early developemnt of Xenopus Laevis, an atlas of the
histology, Springer-Verlag, Berlin, Heidelberg, New York, 1991 (ISBN 3-540-
53740-6).
[18] S. Belikov, P.H. Holmqvist, C. Astrand, O. Wrange, FoxA1 and glucocorticoid
receptor crosstalk via histone H4K16 acetylation at a hormone regulated en-
hancer, Exp. Cell Res. 318 (2012) 61–74.
[19] O. Wrange, J.A. Gustafsson, Separation of the hormone- and DNA-binding sites
of the hepatic glucocorticoid receptor by means of proteolysis, J. Biol. Chem.
253 (1978) 856–865.
[20] J. Asselin, F. Labrie, Y. Gourdeau, C. Bonne, J.P. Raynaud, Binding of [3H] me-
thyltrienolone (R 1881) in rat prostate and human benign prostatic hyper-
trophy (BPH), Steroids 28 (1976) 449–459.
[21] Y. Trottier, Y. Lutz, G. Stevanin, G. Imbert, D. Devys, G. Cancel, F. Saudou,
C. Weber, G. David, L. Tora, et al., Polyglutamine expansion as a pathological
epitope in Huntington’s disease and four dominant cerebellar ataxias, Nature
378 (1995) 403–406.
[22] U.L. Burska, V.J. Harle, K. Coffey, S. Darby, H. Ramsey, D. O’Neill, I.R. Logan,
L. Gaughan, C.N. Robson, Deubiquitinating enzyme Usp12 is a novel co-acti-
vator of the androgen receptor, J. Biol. Chem. 288 (2013) 32641–32650.
[23] G. Almouzni, A.P. Wolffe, Replication-coupled chromatin assembly is required
for the repression of basal transcription in vivo, Genes Dev. 7 (1993)
2033–2047.
